Wednesday, July 8, 2026

Patent intelligence · US

US 10927362

Processable single chain molecules and polypeptides made using same

granted A61KA61K2039/505A61K38/00A61P
Status granted
Linked drugs 2
Pipeline programs 6
Years to expiry 15
Applicant portfolio 140
Patent details — US 10927362
Jurisdiction
US
Status
granted
Grant date
Feb 23, 2021
Expiration
Feb 18, 2041
Claims
14
CPC classes
A61K, A61K2039/505, A61K38/00, A61P
View on Google Patents ↗

Quick answer

US 10927362 (Processable single chain molecules and polypeptides made using same) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Feb 23, 2021. Expires Feb 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
14
CPC classes
A61K, A61K2039/505, A61K38/00, A61P, A61P7/04

More from BIOVERATIV THERAPEUTICS INC.

Related pharmaceutical patents in our USPTO index.

  1. US 12403164

    Lentiviral vector formulations

    BIOVERATIV THERAPEUTICS INC. · Expires Aug 28, 2045

    granted
  2. US 12403183

    Factor VIII polypeptide formulations

    BIOVERATIV THERAPEUTICS INC. · Expires Aug 28, 2045

    granted
  3. US 12391750

    Anti-C1S antibodies and methods of use thereof

    Bioverativ USA Inc. · Expires Aug 14, 2045

    granted
  4. US 12371747

    Methods of reducing immunogenicity against factor VIII in individuals undergoing factor VIII therapy

    BIOVERATIV THERAPEUTICS INC. · Expires Jul 24, 2045

    granted
  5. US 12364774

    Nucleic acid molecules and uses thereof for non-viral gene therapy

    BIOVERATIV THERAPEUTICS INC. · Expires Jul 17, 2045

    granted
  6. US 12268688

    Compositions and methods of use for modified release minoxidil

    Veradermics Incorporated · Expires Apr 3, 2045

    granted
  7. US 12257288

    Methods of inducing immune tolerance to clotting factors

    BIOVERATIV THERAPEUTICS INC. · Expires Mar 20, 2045

    granted
  8. US 12240917

    Anti-complement C1s antibodies and uses thereof

    Bioverativ USA Inc. · Expires Feb 27, 2045

    granted

Frequently asked questions

What is US patent 10927362?

US 10927362 (Processable single chain molecules and polypeptides made using same) is held by BIOVERATIV THERAPEUTICS INC.. Status: granted. Granted Feb 23, 2021. Expires Feb 18, 2041 (15 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 10927362?

BIOVERATIV THERAPEUTICS INC. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 140 pharmaceutical patents for this assignee.

When does US 10927362 expire?

Our index shows an expiration date of Feb 18, 2041 (15 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.